Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shelly McNeil

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Influenza and Other Respiratory Viruses|April 8, 2014
Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccinesGerrit A van Essen, Jiri Beran, Jeanne-Marie Devaster, et al.
Medrxiv : the Preprint Server for Health Sciences|June 29, 2026
A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420May S ElSherif, Kara L Redden, Joanne M Langley, et al.
The Journal of Infectious Diseases|June 8, 2017
Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized TrialLi-Min Huang, Thanyawee Puthanakit, Chiu Cheng-Hsun, et al.
Human Vaccines & Immunotherapeutics|October 4, 2016
Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysisGuillermo M Ruiz-Palacios, Geert Leroux-Roels, Jiri Beran, et al.
The Journal of Infectious Diseases|July 13, 2013
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in childrenJoanne M Langley, Alfonso Carmona Martinez, Archana Chatterjee, et al.
International Journal of Cancer|December 22, 2015
Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE studyS Rachel Skinner, Cosette M Wheeler, Barbara Romanowski, et al.
The Lancet. Infectious Diseases|March 23, 2013
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trialJanet E McElhaney, Jiri Beran, Jeanne-Marie Devaster, et al.
The Lancet. Infectious Diseases|July 5, 2016
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyCosette M Wheeler, S Rachel Skinner, M Rowena Del Rosario-Raymundo, et al.
Influenza and Other Respiratory Viruses|March 13, 2025
The Global Influenza Hospital Surveillance Network: A Multicountry Public Health CollaborationMarta C Nunes, Cecile Chauvel, Sonia M Raboni, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Influenza and Other Respiratory Viruses|April 8, 2014
Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccinesGerrit A van Essen, Jiri Beran, Jeanne-Marie Devaster, et al.
Medrxiv : the Preprint Server for Health Sciences|June 29, 2026
A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420May S ElSherif, Kara L Redden, Joanne M Langley, et al.
The Journal of Infectious Diseases|June 8, 2017
Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized TrialLi-Min Huang, Thanyawee Puthanakit, Chiu Cheng-Hsun, et al.
Human Vaccines & Immunotherapeutics|October 4, 2016
Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysisGuillermo M Ruiz-Palacios, Geert Leroux-Roels, Jiri Beran, et al.
The Journal of Infectious Diseases|July 13, 2013
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in childrenJoanne M Langley, Alfonso Carmona Martinez, Archana Chatterjee, et al.
International Journal of Cancer|December 22, 2015
Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE studyS Rachel Skinner, Cosette M Wheeler, Barbara Romanowski, et al.
The Lancet. Infectious Diseases|March 23, 2013
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trialJanet E McElhaney, Jiri Beran, Jeanne-Marie Devaster, et al.
The Lancet. Infectious Diseases|July 5, 2016
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyCosette M Wheeler, S Rachel Skinner, M Rowena Del Rosario-Raymundo, et al.
Influenza and Other Respiratory Viruses|March 13, 2025
The Global Influenza Hospital Surveillance Network: A Multicountry Public Health CollaborationMarta C Nunes, Cecile Chauvel, Sonia M Raboni, et al.
Pageof 7